查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832331

输血诊断市场（按产品、技术、最终用户和应用）—2025-2032 年全球预测

Blood Transfusion Diagnostics Market by Product, Technology, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，输血诊断市场将成长至 83.2 亿美元，复合年增长率为 10.08%。

主要市场统计数据
基准年2024年 38.6亿美元
预计2025年 42.5亿美元
预测年份：2032年 83.2亿美元
复合年增长率（%） 10.08%

对输血诊断领域发展趋势的策略性介绍以及及时洞察的重要性

诊断技术的发展和政策重点的转变，使输血安全成为医疗保健提供者、诊断开发人员和公共卫生组织的关键策略领域。核酸检测、病原体灭活和血清学平台的快速创新正在重塑捐血筛检和输血安全的运作方式，提高了製造商和实验室的供应链韧性和监管监控标准。因此，需要清晰全面地了解技术发展轨迹、细分市场动态和营运漏洞，以便做出保护病患和维持医疗连续性的决策。

本报告整合了监管更新、临床应用模式、技术检验研究和采购行动的横断面证据，旨在为相关人员提供关于新兴风险和机会的简明方向。报告重点在于设备、耗材、试剂系统和检测方式之间的相互作用，阐明渐进式改善如何带来显着的临床和经济效益。报告始终强调操作可行性、检验路径以及诊断选择与机构能力和公共卫生目标的一致性。

总之，引言为在复杂、快速变化的市场中导航的实用、循证方法奠定了基础，在该市场中，患者安全、成本控制和技术差异化决定了竞争定位和公共健康影响。

技术采用、监管期望和营运模式的转型正在重新定义输血诊断

输血诊断领域正在经历多重相互促进的变革，这些变革正在改变产品开发、实验室工作流程和筹资策略。在技​​术方面，核酸检测已经成熟，同时强大的血清学平台和有针对性的病原体灭活方法也已成熟，从而能够更可靠地检测并降低输血相关风险。这些技术进步也推动了对模组化仪器和整合试剂生态系统的需求，从而缩短了周转时间，并支援在集中式和分散式检测环境中实现更高的通量。

同时，监管要求也日益严格，监管机构优先考虑产品性能检验、上市后监管和可追溯性。这促使供应商需要投资于能够经受严格监控的严格临床验证和品质系统。同时，营运模式正转向医院、独立实验室和研究机构之间的伙伴关係，强调基础设施共用、整合采购和协作验证研究。这种合作趋势有利于实现规模经济，同时允许小型机构透过外包服务和区域中心获得先进的检测能力。

财务压力和供应链中断促使企业更加重视韧性、多元化采购以及尽可能实现在地化生产。因此，市场现有企业和新参与企业正在重新平衡其产品组合，以整合符合不断变化的临床路径和付款人期望的耗材、设备和试剂产品。总而言之，这些转型变革正在增加复杂性，并为能够将技术创新与检验的可扩展部署模型相结合的公司创造新的竞争优势。

2025年美国宣布的关税对输血诊断供应链、成本和策略采购的累积影响

2025年实施的关税对输血诊断供应链产生了多方面的影响，影响了采购决策、成本结构和製造布局。进口零件和设备关税的提高，立即挤压了依赖全球化製造网路的供应商的利润空间，促使许多组织重新评估其供应商基础和库存策略。因此，采购团队优先考虑拥有本地製造能力和/或多元化供应商网路的供应商，以降低波动性并避免单一来源的风险。

除了直接的成本影响外，关税还加速了企业向关键零件（尤其是复杂仪器和大批量耗材）的近岸外包或逐步在岸外包的策略转变。这项转变正在影响资本配置和长期供应链设计，企业正在权衡更高的本地製造成本与降低地缘政治和物流风险之间的利弊。此外，关税也促使一些实验室和医疗系统重新谈判合同，在临床可接受的范围内延长产品生命週期，并探索集团采购安排，以抵消短期价格压力。

监管和报销动态也与关税的影响相互影响。公共和私人采购决策者在评估诊断系统时，越来越严格地审查总体拥有成本，包括生命週期支援和服务弹性。因此，能够展现稳健服务模式、透明定价和灵活供应结构的供应商更有能力客户维繫。同时，一些创新者正在加速试剂和耗材的设计和开发，透过模组化和互通性简化供应链的复杂性，提供替代途径，以减轻关税主导的中断风险​​。

以细分市场为中心的洞察，揭示产品类型、技术模式、最终用户和应用细分市场中存在的策略曲折点

产品细分显示耗材及配件、仪器、试剂及试剂套件之间的清晰分层，每种都有不同的商业动态和操作要求。微孔盘和微量吸管尖耗材及配件是大批量、成本敏感的物品，因此供应的连续性和品管至关重要，迫使买家优先考虑可靠的供应商和有效的品质系统。核酸分析仪、病原体灭活系统和血清学分析仪等仪器是资本密集型投资，使用寿命长，检验负担重，因此有利于提供整合服务协议和可互通软体的供应商。扩增试剂、抗体试剂和 DNA 萃取试剂套件等试剂和试剂套件将技术特异性与监管复杂性结合在一起，要求製造商保持严格的批间一致性，并对新病原体和检测更新做出快速反应。

技术的细分进一步细分了开发商和买家的优先顺序。核酸检测方法，例如PCR、即时PCR和转录媒介增幅，具有较高的分析灵敏度，通常是病毒标记早期检测的首选，但也需要训练有素的人员和强大的检测基础设施。使用阿莫沙林、亚甲蓝或核黄素的病原体灭活技术因其惰性血液成分中多种威胁的潜力而日益受到评估，其采用取决于已证实的临床疗效、工作流程相容性和成本效益。血清学检测平台，包括CLIA、ELISA和横向流动化验，在免疫分析和筛检工作流程中仍然至关重要，通量、特异性和照护现场之间的权衡驱动着采购决策。

最终用户的细分——医院血库、独立实验室和研究机构——影响购买行为和服务期望。医院血库优先考虑营运的连续性、与临床工作流程的兼容性以及在时间敏感条件下供应商的反应能力；而独立实验室通常更重视通量、检测标准化以及支援多客户的灵活设备空间。研究机构则倾向于优先考虑检测的灵活性以及获得新试剂和平台进行实验检验的便利性，从而促进创新方法的早期采用，并将其转化为常规筛检。

应用类别（例如捐血筛检、品管或输血安全）决定了性能要求和验证途径。捐血筛检任务（例如免疫血液学检测和病毒标记筛检）需要高灵敏度和特异性，以最大限度地降低输血传染感染疾病的风险。品管控制（包括外部能力验证和内部品管）对于维持诊断准确性和法规遵循至关重要。输血安全任务（例如血型鑑定和病原体灭活）需要可互通的工作流程和检验的仪器/试剂组合，以确保整个输血链中的患者治疗结果和可追溯性。

区域视角突显全球市场独特的招募模式、法规环境和业务重点

美洲地区拥有先进的实验室基础设施、完善的医院网络，并在核酸检测和病原体控制技术方面积极投入。该地区的医疗保健系统通常优先考虑快速部署、整合服务合约以及与电子健康记录和血液管理平台的互通性。相关政策和采购机制强调检验的临床性能和可追溯性，从而满足了对全面的仪器和试剂生态系统以及强大的供应商支援模式的需求。

欧洲、中东和非洲是多元化市场，各地区监管环境、资金筹措模式和基础建设成熟度差异显着。在许多欧洲市场，严格的监管途径和集中采购框架有利于拥有可靠合规性和跨境服务能力的供应商。中东市场正在投资升级其实验室能力，有时透过官民合作关係关係进行。同时，非洲市场经常需要适应资源受限环境的解决方案，强调稳健性、易用性和较低的整体拥有成本。在全部区域，策略采用通常依赖当地检验研究、区域分销网络和培训计划，以确保可持续采用。

亚太地区的特点是诊断能力的快速现代化、充满活力的本地製造生态系统以及不同经济体之间差异化的采用曲线。该地区的一些市场以积极采用照护现场血清学检测和可扩展核酸检测平台而着称，这得益于公共卫生计画和不断扩张的私人医疗网络。该地区的供应链优势和政策重点加速了技术转移和合作开发，但监管趋同和标准协调是持续存在的挑战，影响跨境商业化策略。

竞争对手层面的动态塑造输血诊断领域的竞争、合作与创新策略

例如，受访的输血诊断领域的公司正在寻求垂直整合、策略伙伴关係和选择性专业化相结合的方式，以平衡规模优势和技术差异化。提供整合仪器、试剂和服务的製造商可以透过简化验证途径和确保端到端责任制，向大型机构投资者提供极具吸引力的价值提案。相反，专注于特定技术或试剂化学成分的专业公司通常能够推动创新，并凭藉有针对性的功效和成本绩效优势吸引早期采用者。

诊断公司、学术中心和临床网路之间的合作正日益成为加速检测检验和扩大临床接受度的机制。此类合作为真实世界证据的生成提供了可行的途径，并能够透过利用分散式临床测试和共用数据平台来缩短从开发到应用的时间。同时，服务和分销伙伴关係在扩大地理覆盖范围和确保供应连续性方面发挥关键作用，尤其是在基础设施不均衡的地区。

投资模式表明，资金正被配置在自动化、数位连接和多重检测领域。在以总拥有成本和营运韧性为关键采购标准的环境下，那些拥有强大售后支援、远距离诊断能力和持续改善管道的公司更有能力留住客户。总体而言，公司策略正围绕着灵活性、临床证据和供应可靠性——这些是竞争成功的关键决定因素——进行整合。

为产业领导者提供切实可行的建议，以加强输血诊断领域的市场定位、弹性和临床影响

企业应优先投资模组化平台和可互通的试剂生态系统，以减轻医院实验室的检验负担，并促进其快速融入现有工作流程。透过设计既能满足高通量集中式实验室需求，又能满足分散式检查需求的解决方案，供应商可以扩大其潜在市场，并降低依赖单一通路带来的风险。同时，改善服务模式，例如预测性维护、远端监控和透明的生命週期成本揭露，可以增强买家信心，提升购买意愿。

鑑于近期贸易政策的变化，企业应重新考虑策略采购和製造，以优化冗余和本地回应能力。企业应评估近岸外包选项、双重采购策略和库存优化技术，以在控製成本的同时保持连续性。儘早与监管机构沟通并参与协调倡议，可以减少市场摩擦，并为跨境商业化开闢清晰的道路。重要的是，企业应与临床网络和公共卫生组织建立合作伙伴关係，以产生真实世界证据，检验其性能并展示临床效用。

最后，领导者应将资源分配给员工发展和变革管理，以确保临床实施的顺利进行。投资培训模组、虚拟支援和协作检验专案可以降低实施风险并加速采用。透过实施这些建议，组织可以充分利用技术进步，同时保持营运弹性，并在输血安全方面取得显着改善。

对调查方法、数据三角测量过程以及分析所依据的检验通讯协定进行清晰的解释

研究方法结合了对官方监管文件、同行评审临床研究、专利申请和技术白皮书的系统综述，以及实验室主任、采购专业人员和诊断开发人员的结构化访谈。检视了二手资讯的相关性和时效性，并进行了一手访谈，以了解从业人员对工作流程限制、验证痛点和采购优先顺序的见解。对这些输入资料进行三角测量，以确定一致的主题并协调不同的观点。

分析方法包括对访谈记录进行定性编码、整合监管指南以映射验证要求，以及对敏感性、特异性、吞吐量和整合复杂性等技术属性进行比较评估。情境分析检验了供应中断和政策变化对营运的影响，敏感度检验则确保了结论在采用时间和采购行为的各种可能变化下依然稳健。在适当的情况下，我们开发了用例来说明实作路径，并强调了从早期采用者那里获得的经验教训。

品质保证措施包括目标细分市场专家的同侪审查、技术声明与监管文件和临床文献的交叉检验，以及透过相关人员的回馈不断完善研究结果。原始资料收集过程中遵循伦理考量和保密保护原则，结论强调实际意义而非推测性预测。

结论：总结了输血诊断领域的策略意义和相关人员的基本考虑因素。

输血诊断领域正处于曲折点，技术进步、严格的监管环境和供应链现状交织在一起，重新定义了机会和风险。相关人员若能协调产品开发和临床检验需求，投资于弹性供应链架构，并优先考虑可互通的解决方案，将更有能力满足机构和公共卫生的需求。由于仪器性能、试剂品质和营运支援之间的相互作用决定了实际影响，因此策略重点应放在证据生成、卓越服务和灵活的部署模式上。

此外，近期的政策发展和贸易行动凸显了适应性筹资策略和区域合作的重要性。积极应对关税相关漏洞、及早与监管机构沟通并与临床网络建立合作伙伴关係关係的组织，可以减少实施摩擦并加速采用。总而言之，本部分认可规范的执行，即在技术创新与验证、物流和临床工作流程相容性等实际考量之间取得平衡。

此次整合旨在帮助决策者确定投资优先顺序、优化筹资策略并设计实施方案，从而在管理成本和营运风险的同时提高输血安全性。透过采用务实的数据主导方法，相关人员可以将技术进步与患者治疗效果的可衡量改善联繫起来。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 引入新一代核酸检测平台，提高捐血病原体检测灵敏度
  • 采用人工智慧和机器学习演算法，实现输血中心血型分型和交叉配对检查工作流程的自动化
  • 整合区块链驱动的可追溯性解决方案，以确保血液供应链的安全并降低输血相关的安全风险。
  • 扩大微流体照护现场诊断设备的应用，以便在紧急情况和农村地区进行快速床边血液相容性检测
  • 开发一种高性能多重免疫检测，用于在捐赠者筛检期间同时检测多种输血性行为感染

第六章 2025年美国关税的累积影响

第七章 人工智慧的累积影响，2025年

第 8 章：输血诊断市场（按产品）

  • 耗材及配件
    • 微孔盘
    • 微量吸管尖
  • 装置
    • NAT分析仪
    • 病原体减少系统
    • 血清分析仪
  • 试剂和套件
    • 扩增试剂
    • 抗体试剂
    • DNA萃取试剂套件

9. 输血诊断市场（依技术）

  • 核酸检测
    • PCR
    • 即时PCR
    • 转录介导的扩增
  • 病原体减少技术
    • 阿莫托萨伦
    • 亚甲基蓝
    • 核黄素
  • 血清学检测
    • CLIA
    • ELISA
    • 横向流动化验

第 10 章。输血诊断市场（按最终用户）

  • 医院血库
  • 独立实验室
  • 研究所

第11章输血诊断市场的应用

  • 捐血筛检
    • 免疫血液学检测
    • 病毒标记筛检
  • 品管
    • 外部能力测试
    • 内部品管
  • 输血安全
    • 血型测定
    • 病原体灭活

第 12 章：按地区分類的输血诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章。输血诊断市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。按国家/地区分類的输血诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Ortho Clinical Diagnostics, Inc.
    • Grifols, SA
    • Thermo Fisher Scientific Inc.
    • Immucor, Inc.
    • Bio-Rad Laboratories, Inc.
    • Danaher Corporation
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Siemens Healthineers AG
    • bioMerieux SA
Product Code: MRR-437D45958222

The Blood Transfusion Diagnostics Market is projected to grow by USD 8.32 billion at a CAGR of 10.08% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.86 billion
Estimated Year [2025] USD 4.25 billion
Forecast Year [2032] USD 8.32 billion
CAGR (%) 10.08%

Strategic introduction to the evolving blood transfusion diagnostics landscape and why timely insights matter

Advances in diagnostic technologies and shifting policy priorities have converged to make blood transfusion safety a critical strategic domain for healthcare providers, diagnostic developers, and public health agencies. Rapid innovations in nucleic acid testing, pathogen reduction, and serological platforms are reshaping how donation screening and transfusion safety are operationalized, while supply chain resilience and regulatory scrutiny are raising the bar for manufacturers and laboratories alike. Consequently, organizations need a clear, synthesized view of technological trajectories, segment dynamics, and operational vulnerabilities to make decisions that protect patients and maintain continuity of care.

This report synthesizes cross-cutting evidence from regulatory updates, clinical adoption patterns, technology validation studies, and procurement behavior to provide stakeholders with a concise orientation to emerging risks and opportunities. By highlighting the interplay between instrumentation, consumables, reagent systems, and testing modalities, the analysis illuminates where incremental improvements yield outsized clinical and economic benefits. Throughout, emphasis is placed on operational feasibility, validation pathways, and the alignment of diagnostic choices with institutional capacity and public health objectives.

In short, the introduction lays the groundwork for a pragmatic, evidence-driven approach to navigating a complex and fast-moving market where patient safety, cost containment, and technological differentiation determine competitive positioning and public health impact.

Transformative shifts in technology adoption, regulatory expectations, and operational models redefining transfusion diagnostics

The diagnostic landscape for blood transfusion is experiencing multiple, mutually reinforcing shifts that are transforming product development, laboratory workflows, and procurement strategies. On the technology front, the maturation of nucleic acid testing modalities alongside robust serological platforms and targeted pathogen reduction methods is enabling more reliable detection and mitigation of transfusion-related risks. These technical advances are accompanied by greater demand for modular instrumentation and integrated reagent ecosystems that reduce hands-on time and support higher throughput in centralized and decentralized testing environments.

Regulatory expectations are concurrently tightening, with authorities prioritizing validated performance, post-market surveillance, and traceability. This has intensified the need for suppliers to invest in rigorous clinical validation and quality systems that can withstand heightened scrutiny. At the same time, operational models are shifting toward partnerships between hospitals, independent laboratories, and research institutes that emphasize shared infrastructure, consolidated procurement, and joint validation studies. This collaborative trend supports economies of scale while enabling smaller facilities to access advanced testing capabilities through outsourced services or regional hubs.

Financial pressures and supply chain disruptions have encouraged a stronger emphasis on resilience, diversification of sourcing, and localized manufacturing where practicable. As a result, market incumbents and new entrants are rebalancing portfolios to integrate consumables, instruments, and reagent offerings that align with evolving clinical pathways and payer expectations. Taken together, these transformative shifts create both heightened complexity and new levers for competitive advantage for organizations that can align technological innovation with validated, scalable deployment models.

Cumulative implications of United States tariff measures announced in 2025 on supply chains, costs, and strategic sourcing in transfusion diagnostics

Tariff actions introduced in 2025 have had multifaceted repercussions across the supply chain for blood transfusion diagnostics, influencing sourcing decisions, cost structures, and manufacturing footprints. Increased duties on imported components and instruments have created immediate pressure on margins for suppliers that rely on globalized manufacturing networks, prompting many organizations to reassess their vendor base and inventory practices. As a result, procurement teams are prioritizing suppliers with localized production capabilities or diversified supplier networks to mitigate volatility and avoid single-source exposure.

In addition to direct cost effects, tariffs have accelerated strategic shifts toward nearshoring and incremental onshoring of critical components, particularly for complex instruments and high-volume consumables. This movement has implications for capital allocation and long-term supply chain design, with firms weighing the trade-offs between higher local manufacturing costs and reduced geopolitical and logistics risk. Furthermore, the tariffs have prompted some labs and health systems to renegotiate contracts, extend product lifecycles where clinically acceptable, and explore pooled purchasing agreements to offset short-term price pressures.

Regulatory and reimbursement dynamics also interact with tariff impacts. Decision-makers at public and private purchasers are increasingly scrutinizing total cost of ownership, including lifecycle support and service resilience, when evaluating diagnostic systems. Therefore, vendors that can demonstrate robust service models, transparent pricing, and flexible supply arrangements are better positioned to retain institutional customers. In parallel, some innovators have accelerated development of reagent and consumable designs that simplify supply chain complexity through modularity and interoperability, providing an alternate pathway to reduce exposure to tariff-driven disruptions.

Segment-focused insights that illuminate where product types, technology modalities, end users, and application areas create strategic inflection points

Product segmentation shows a clear stratification between consumables and accessories, instruments, and reagents and kits, each with distinct commercial dynamics and operational requirements. Consumables and accessories such as microplates and pipette tips are high-volume, cost-sensitive items where supply continuity and quality control are paramount, compelling purchasers to prioritize trusted suppliers and validated quality systems. Instruments, including nucleic acid testing analyzers, pathogen reduction systems, and serology analyzers, represent capital-intensive investments with long service lifecycles and significant validation burdens, which favor suppliers that offer integrated service contracts and interoperable software. Reagents and kits, spanning amplification reagents, antibody reagents, and DNA extraction kits, combine technical specificity with regulatory complexity, requiring manufacturers to maintain stringent lot-to-lot consistency and rapid responsiveness to emergent pathogens and assay updates.

Technology segmentation further refines priorities for developers and buyers. Nucleic acid testing modalities such as PCR, real-time PCR, and transcription-mediated amplification deliver high analytical sensitivity and are often preferred for early detection of viral markers, but they also require trained personnel and robust laboratory infrastructure. Pathogen reduction technologies employing amotosalen, methylene blue, or riboflavin are increasingly valued for their potential to inactivate a broad spectrum of threats in blood components, and their adoption hinges on demonstrated clinical efficacy, workflow compatibility, and cost-effectiveness. Serological testing platforms, including CLIA, ELISA, and lateral flow assays, remain critical for immune profiling and screening workflows, with trade-offs between throughput, specificity, and point-of-care applicability shaping procurement decisions.

End user segmentation - hospital blood banks, independent laboratories, and research institutes - influences purchasing behavior and service expectations. Hospital blood banks prioritize operational continuity, compatibility with clinical workflows, and supplier responsiveness under time-sensitive conditions, whereas independent laboratories often focus on throughput, assay standardization, and flexible instrument footprints that support multiple clients. Research institutes tend to prioritize assay flexibility and access to novel reagents and platforms for experimental validation, fostering early-stage adoption of innovative methods that can later be translated into routine screening.

Application segmentation - donation screening, quality control, and transfusion safety - determines performance requirements and validation pathways. Donation screening activities such as immunohematology testing and viral marker screening demand high sensitivity and specificity to minimize risk of transfusion-transmitted infections. Quality control practices that include external proficiency testing and internal quality control are essential for maintaining diagnostic accuracy and regulatory compliance. Transfusion safety tasks like blood group typing and pathogen inactivation require interoperable workflows and validated device-reagent pairings to ensure patient outcomes and traceability throughout the transfusion chain.

Regional perspectives highlighting distinct adoption patterns, regulatory climates, and operational priorities across global markets

The Americas region exhibits a combination of advanced laboratory infrastructure, well-established hospital networks, and active investment in both nucleic acid testing and pathogen mitigation technologies. Healthcare systems in this region often prioritize rapid deployment, integrated service agreements, and interoperability with electronic medical records and blood management platforms. Policy and procurement mechanisms emphasize validated clinical performance and traceability, which in turn supports demand for comprehensive instrument-reagent ecosystems and robust vendor support models.

Europe, Middle East & Africa present a heterogeneous landscape in which regulatory nuances, funding models, and infrastructure maturity vary considerably between territories. In many European markets, stringent regulatory pathways and centralized procurement frameworks favor suppliers with proven compliance track records and pan-border service capabilities. Middle Eastern markets are investing in upgrading laboratory capacities, sometimes through public-private partnerships, while African markets frequently require solutions adapted to constrained-resource settings, emphasizing ruggedness, ease of use, and lower total cost of ownership. Across this combined region, strategic adoption often depends on local validation studies, regional distribution networks, and training programs that ensure sustainable implementation.

Asia-Pacific is characterized by rapid modernization of diagnostic capabilities, active local manufacturing ecosystems, and heterogeneous adoption curves across economies. Some markets in the region are notable for aggressive adoption of point-of-care serological assays and scalable nucleic acid testing platforms, driven by both public health programs and expanding private healthcare networks. The region's supply chain strengths and policy priorities can accelerate technology transfer and collaborative development, but regulatory convergence and harmonized standards remain ongoing challenges that influence cross-border commercialization strategies.

Company-level dynamics shaping competition, collaboration, and innovation strategies within blood transfusion diagnostics

Competitors in the transfusion diagnostics space are pursuing a mix of vertical integration, strategic partnerships, and selective specialization to balance scale advantages with technological differentiation. Manufacturers that combine instruments, reagents, and service offerings can create compelling value propositions for large institutional buyers by simplifying validation pathways and ensuring end-to-end accountability. Conversely, specialized firms that focus on a narrow set of technologies or reagent chemistries often drive innovation and can capture early adopter segments through targeted efficacy and cost-performance advantages.

Collaborations between diagnostic firms, academic centers, and clinical networks are increasingly common as a mechanism to accelerate assay validation and broaden clinical acceptance. These alliances support pragmatic pathways to real-world evidence generation and can shorten the time from development to adoption by leveraging distributed clinical studies and shared data platforms. At the same time, service and distribution partnerships play a critical role in expanding geographic reach and ensuring supply continuity, particularly in regions with uneven infrastructure.

Investment patterns reveal that capital is being allocated toward automation, digital connectivity, and assay multiplexing, as buyers seek throughput gains and reduced hands-on time. Firms that demonstrate robust post-sale support, remote diagnostics capabilities, and continuous improvement pipelines are better positioned to retain customers in an environment where total cost of ownership and operational resilience are key purchasing criteria. Overall, company strategies are converging around flexibility, clinical evidence, and supply reliability as dominant determinants of competitive success.

Practical, actionable recommendations for industry leaders to strengthen market positioning, resilience, and clinical impact in transfusion diagnostics

Organizations should prioritize investments in modular platforms and interoperable reagent ecosystems that reduce validation burden for hospital laboratories and facilitate rapid integration into existing workflows. By designing solutions that accommodate both high-throughput central labs and decentralized testing scenarios, suppliers can expand addressable markets and mitigate risks associated with single-channel dependence. In parallel, enhancing service models with predictive maintenance, remote monitoring, and transparent lifecycle cost disclosures will increase buyer confidence and improve retention.

Strategic sourcing and manufacturing should be revisited in light of recent trade policy shifts to optimize for redundancy and regional responsiveness. Firms should evaluate nearshoring options, dual-sourcing strategies, and inventory optimization techniques to preserve continuity while controlling costs. Engaging early with regulatory authorities and participating in harmonization initiatives can reduce time-to-market friction and create clearer pathways for cross-border commercialization. Importantly, companies should cultivate collaborative partnerships with clinical networks and public health entities to generate real-world evidence that validates performance and demonstrates clinical utility.

Finally, leaders should allocate resources to workforce training and change management to ensure smooth clinical adoption. Investing in training modules, virtual support, and joint validation programs will reduce implementation risk and accelerate uptake. Executing these recommendations will position organizations to capitalize on technological advances while maintaining operational resilience and delivering measurable improvements in transfusion safety.

Transparent description of the research methodology, data triangulation processes, and validation protocols underpinning the analysis

The research approach combined systematic review of public regulatory documents, peer-reviewed clinical studies, patent filings, and technical white papers with structured interviews of laboratory directors, procurement specialists, and diagnostic developers. Secondary sources were vetted for relevance and recency, and primary interviews were conducted to capture practitioner insights on workflow constraints, validation pain points, and procurement priorities. Data were triangulated across these inputs to identify consistent themes and to reconcile divergent perspectives.

Analytical techniques included qualitative coding of interview transcripts, synthesis of regulatory guidance to map validation requirements, and comparative assessment of technology attributes such as sensitivity, specificity, throughput, and integration complexity. Scenario analysis was employed to examine the operational effects of supply disruptions and policy changes, while sensitivity checks ensured that conclusions remained robust across plausible variations in adoption timing and procurement behavior. Where appropriate, case studies were developed to illustrate implementation pathways and to highlight lessons learned from early adopters.

Quality assurance measures included peer review by subject matter experts, cross-validation of technical claims against regulatory filings and clinical literature, and iterative refinement of findings based on stakeholder feedback. Ethical considerations and confidentiality protections governed primary data collection, and conclusions emphasize practical implications rather than speculative forecasts.

Conclusion synthesizing strategic implications and the essential considerations for stakeholders navigating the transfusion diagnostics domain

The blood transfusion diagnostics landscape is at an inflection point where technical progress, regulatory rigor, and supply chain realities intersect to redefine opportunity and risk. Stakeholders that align product development with clinical validation needs, invest in resilient supply chain architectures, and prioritize interoperable solutions will be better positioned to meet institutional demands and public health imperatives. The interplay between instrument performance, reagent quality, and operational support determines real-world impact, and accordingly, strategic emphasis should be placed on evidence generation, service excellence, and flexible deployment models.

Moreover, recent policy developments and trade measures underscore the importance of adaptive sourcing strategies and regional engagement. Organizations that proactively address tariff-related vulnerabilities, engage regulators early, and build collaborative partnerships with clinical networks will reduce implementation friction and accelerate adoption. In sum, the sector rewards disciplined execution that balances innovation with practical considerations of validation, logistics, and clinical workflow compatibility.

This synthesis is intended to help decision-makers prioritize investments, refine procurement strategies, and design implementation plans that enhance transfusion safety while managing cost and operational risk. By adopting a pragmatic, data-driven approach, stakeholders can translate technological advances into measurable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Implementation of next-generation nucleic acid testing platforms to enhance pathogen detection sensitivity in blood donations
  • 5.2. Adoption of artificial intelligence and machine learning algorithms for automated blood typing and crossmatching workflows in transfusion centers
  • 5.3. Integration of blockchain-enabled traceability solutions to secure the blood supply chain and mitigate transfusion-related safety risks
  • 5.4. Expansion of microfluidic point-of-care diagnostic devices for rapid bedside blood compatibility testing in emergency and rural settings
  • 5.5. Development of high-throughput multiplexed immunoassays for simultaneous detection of multiple transfusion-transmissible infections during donor screening

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Transfusion Diagnostics Market, by Product

  • 8.1. Consumables & Accessories
    • 8.1.1. Microplates
    • 8.1.2. Pipette Tips
  • 8.2. Instruments
    • 8.2.1. Nat Analyzers
    • 8.2.2. Pathogen Reduction Systems
    • 8.2.3. Serology Analyzers
  • 8.3. Reagents & Kits
    • 8.3.1. Amplification Reagents
    • 8.3.2. Antibody Reagents
    • 8.3.3. Dna Extraction Kits

9. Blood Transfusion Diagnostics Market, by Technology

  • 9.1. Nucleic Acid Testing
    • 9.1.1. Pcr
    • 9.1.2. Real Time Pcr
    • 9.1.3. Transcription Mediated Amplification
  • 9.2. Pathogen Reduction Technology
    • 9.2.1. Amotosalen
    • 9.2.2. Methylene Blue
    • 9.2.3. Riboflavin
  • 9.3. Serological Testing
    • 9.3.1. Clia
    • 9.3.2. Elisa
    • 9.3.3. Lateral Flow Assays

10. Blood Transfusion Diagnostics Market, by End User

  • 10.1. Hospital Blood Banks
  • 10.2. Independent Laboratories
  • 10.3. Research Institutes

11. Blood Transfusion Diagnostics Market, by Application

  • 11.1. Donation Screening
    • 11.1.1. Immunohematology Testing
    • 11.1.2. Viral Marker Screening
  • 11.2. Quality Control
    • 11.2.1. External Proficiency Testing
    • 11.2.2. Internal Quality Control
  • 11.3. Transfusion Safety
    • 11.3.1. Blood Group Typing
    • 11.3.2. Pathogen Inactivation

12. Blood Transfusion Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Transfusion Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Transfusion Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Ortho Clinical Diagnostics, Inc.
    • 15.3.2. Grifols, S.A.
    • 15.3.3. Thermo Fisher Scientific Inc.
    • 15.3.4. Immucor, Inc.
    • 15.3.5. Bio-Rad Laboratories, Inc.
    • 15.3.6. Danaher Corporation
    • 15.3.7. F. Hoffmann-La Roche Ltd
    • 15.3.8. Abbott Laboratories
    • 15.3.9. Siemens Healthineers AG
    • 15.3.10. bioMerieux SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BLOOD TRANSFUSION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BLOOD TRANSFUSION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD TRANSFUSION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY MICROPLATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PIPETTE TIPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NAT ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMPLIFICATION REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DNA EXTRACTION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY AMOTOSALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY METHYLENE BLUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RIBOFLAVIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CLIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY HOSPITAL BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY IMMUNOHEMATOLOGY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY VIRAL MARKER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY EXTERNAL PROFICIENCY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INTERNAL QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY BLOOD GROUP TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN INACTIVATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY DONATION SCREENING, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY QUALITY CONTROL, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TRANSFUSION SAFETY, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID TESTING, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BLOOD TRANSFUSION DIAGNOSTICS MARKET SIZE, BY PATHOGEN REDUCTION TECHNOLOGY, 2018-2024 (USD MILLION)

TABLE 28